| Literature DB >> 27714704 |
Li Du1, Yun Xia2, Yunyan He3, Qingquan Pu1, Ruoyi Hua1, Wenyao Wu1.
Abstract
Invasive aspergillosis (IA) is a life-threatening infection in immunocompromised patients, rapid and sensitive detection of Aspergillus from clinical samples has been a major challenge in the early diagnosis of IA. An enzyme-linked immunosorbent assay of nucleic acid sequence-based amplification (NASBA-ELISA) was developed to fulfil the need for the efficient diagnosis of these infections. The primers targeting 18S rRNA were selected for the amplification of Aspergillus RNA by the isothermal digoxigenin (DIG)-labeling NASBA process. The DIG-labeled RNA amplicons were hybridized with a specific biotinylated DNA probe immobilized on streptavidin-coated microtiter plate. The hybrids were colorimetrically detected by the addition of an anti-DIG antibodies linked to ALP and substrate (disodium 4-nitrophenyl phosphate). The detection limit of the Aspergillus NABSA-ELISA system was 1 CFU and the RNA in non-target bacteria or fungus was not amplified. The performance of this NASBA-ELISA compared to RT-PCR and galactomannan (GM) was evaluated by testing blood samples from 86 patients at high risk for IA. The sensitivity of NASBA-ELISA, RT-PCR and GM-ELISA was 80.56 % (95 % CI 63.98-91.81), 72.22 % (95 % CI 54.81-85.80), 58.33 % (95 % CI 40.76-74.49), respectively, and the specificity was 80.00 % (95 % CI 66.28-89.97), 84.00 % (95 % CI 70.89-92.83), 82.00 % (95 % CI 68.56-91.42). The efficiency of the three methods in various combinations was also evaluated. Combination of NASBA-ELISA and GM-ELISA testing achieved perfect specificity (100 %; 95 % CI 92.89-100) and perfect positive predictive value (100 %; 95 % CI 83.16-100). The best sensitivity (97.22 %; 95 % CI 85.47-99.93) and the highest Youden index (0.652) were obtained by testing with both NASBA and RT-PCR in parallel. In conclusion, the NASBA-ELISA assay consists of an alternative process for large-scale samples detection with semi-quantitative results and provides good clinical performance without resorting to expensive equipment. This assay makes it possible for the NASBA based RNA diagnosis to become a routine work in laboratories in less developed countries with fewer resources.Entities:
Keywords: GM-EIA; Invasive aspergillosis; NASBA-ELISA; RT-PCR
Year: 2016 PMID: 27714704 PMCID: PMC5053951 DOI: 10.1186/s13568-016-0266-0
Source DB: PubMed Journal: AMB Express ISSN: 2191-0855 Impact factor: 3.298
Nucleotide sequences of oligonucleotide primers and probe used in this study
| Primers/probe | Sequence (5′-3′) | Length (bp) |
|---|---|---|
| Primers 2.1 | 5′-GCCGCGGTAATTCCAGCTCCAATA-3′ | 24 |
| Primers 1.2 + T7a | 5′- | 47 |
| Hybridization probe | Bioth-GGTCCGCCTCACCGCGAGTACTG-3′ | 20 |
| NASBA product | 243 |
aUnderlining indicates the T7 promoter region
Fig. 1Analytical sensitivity of NASBA followed by 1 % agarose gel electrophoresis with Goldview for tenfold serial dilutions of genomic RNA extracted from a saline solution containing 105 CFU Aspergillus spores. Lane 1 105 CFU; lane 2 104 CFU; lane 3 103 CFU; lane 4 102 CFU; lane 5 10 CFU; lane 6 1 CFU; lane 7 0.1 CFU; lane 8, negative control. The detection limit was 1 CFU
Fig. 2Detection of DIG-labeled NASBA products by the microplate hybridization system. NASBA was performed in the presence of 105 CFU Aspergillus spores and then NASBA product was twofold serially diluted before DIG-detection ELISA system (filled square). Negative control consists of NASBA reaction performed in the absence of Aspergillus (open square). Results are averages of triplication analysis
Fig. 3Sensitivity of the NASBA-ELISA for molecular detection of Aspergillus 18S rRNA. Tenfold serial dilutions of Aspergillus (105 CFU) were prepared and used for 18S rRNA extraction and DIG-labeling NASBA amplification.Then 5 μL of the NASBA product was used in DIG-detection NASBA-ELISA system. Each dilution was analyzed in duplicate
Fig. 4Correlation between log-transformed individual measurements of Aspergillus spores and absorbance readings. The determination coefficient between NASBA-ELISA OD and log[spores concentration] was 0.986
Fig. 5Analysis of specificity of the NASBA-ELISA DIG-detection system. NASBA-ELISA was performed with non-target nucleic acids. NASBA-ELISA was performed on 18S rRNA of A.fumigatus as a positive control. DIG-detection ELISA was performed on H2O as a negative control. The results are means of triplication analysis
Assay concordance on a patient basis
| Test combination | No. of population positive by test or test combination | |
|---|---|---|
| Proven/probable (n = 36) | No IA (n = 50) | |
| NASBA-ELISA, | 18 | 0 |
| NASBA-ELISA, | 2 | 3 |
| NASBA-ELISA, GM positive | 2 | 0 |
|
| 1 | 1 |
| NASBA-ELISA positive | 7 | 7 |
|
| 5 | 5 |
| GM positive | 0 | 8 |
| NASBA-ELISA, | 1 | 26 |
Fig. 6ROC curve of the NASBA-ELISA assay. The ROC analysis is based on optical density values. Area under the curve = 0.760 (95 % CI 0.650–0.870). Diagonal segments are produced by ties
Performance parameters for GM ELISA, Aspergillus RT-PCR, and Aspergillus NASBA-ELISA when testing cases of proven/probable IA
| Parameter | NASBA-ELISA | RT-PCR | GM-ELISA |
|---|---|---|---|
| Sensitivity [% (95 % CI)] |
| 72.22 (54.81–85.80) | 58.33 (40.76–74.49)* |
| Specificity [% (95 % CI)] | 80.00 (66.28–89.97) |
| 82.00 (68.56–91.42) |
| Positive likelihood ratio | 4.03 (2.26–7.17) |
| 3.24 (1.69–6.23) |
| Negative likelihood ratio | 0.24 (0.12–0.48) | 0.33 (0.19–0.57) |
|
| PPV [% (95 % CI)] | 74.36 (57.87–86.96) |
| 70.00 (50.60–85.27) |
| NPV [% (95 % CI)] |
| 80.77 (67.47–90.37) | 73.21 (59.70–84.17) |
| Youden index |
| 0.56 | 0.40 |
| κ statistic |
| 0.57 | 0.41 |
Combined analysis for both proven IA (n = 9) and probable IA (n = 27)
Best performance values are highlighted in italics
* P < 0.05 versus NASBA-ELISA
Combined assay performance for GM ELISA, Aspergillus RT-PCR, and Aspergillus NASBA-ELISA when testing cases of proven/probable IA
| parameter | NASBA-ELISA ora RT-PCR | NASBA-ELISA andb RT-PCR | NASBA-ELISA or GM-ELISA | NASBA-ELISA and GM-ELISA | RT-PCR or GM-ELISA | RT-PCR and GM-ELISA |
|---|---|---|---|---|---|---|
| Sensitivity |
| 55.56 (38.10–72.06) | 83.33 (67.19–93.63) | 55.56 (38.10–72.06) | 77.78 (60.85–89.88) | 52.78 (35.49–69.59) |
| Specificity | 68.00 (53.30–80.48) | 94.00 (83.45–98.75) | 62.00 (47.17–75.35) |
| 66.00 (51.23–78.79) | 98.00 (89.35–99.95) |
| Positive likelihood ratio | 3.04 (2.02–4.57) | 9.26 (2.98–28.82) | 2.19 (1.50–3.22) | Infinity | 2.29 (1.50–3.49) |
|
| Negative likelihood ratio | 0.04 (0.01–0.28) | 0.47 (0.33–0.69) | 0.27 (0.13–0.58) | 0.44 (0.31–0.64) | 0.34 (0.18–0.64) |
|
| PPV [% (95 % CI)] | 68.63 (54.11–80.89) | 86.96 (66.41–97.22) | 61.22 (46.24–74.80) |
| 62.22 (46.54–76.23) | 95.00 (75.13–99.87) |
| NPV [% (95 % CI)] |
| 74.60 (62.06–84.73) | 83.78 (67.99–93.81) | 75.76 (63.64–85.46) | 80.49 (65.13–91.18) | 74.24 (61.99–84.22) |
| Youden index |
| 0.496 | 0.453 | 0.556 | 0.438 | 0.508 |
Combined analysis for both proven IA (n = 9) and probable IA (n = 27)
Best performance values are highlighted in italics
a “or” indicates that at least one of the assays is required to be positive
b “and” indicates that both assays are required to be positive before a patient is considered positive